Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.

Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to ...

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran ...
Barron's

Biogen Inc.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, ...
Hosted on MSN

Pharma giants post strong Q1 earnings and lift forecasts

Major pharmaceutical companies, including GSK, AstraZeneca, Biogen, and Ionis, reported first-quarter 2026 results that ...